Cite
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
MLA
Tobias L. Lenz, et al. “Human Leukocyte Antigen Variation Is Associated with Adverse Events of Checkpoint Inhibitors.” European Journal of Cancer, vol. 107, Jan. 2019, pp. 8–14. EBSCOhost, https://doi.org/10.1016/j.ejca.2018.11.009.
APA
Tobias L. Lenz, Fiamma Berner, David Bomze, Mirjam Fässler, Christoph Driessen, Martin Früh, Omar Ali, Antonio Cozzio, Lukas Flatz, Stefan Diem, & Markus Jörger. (2019). Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. European Journal of Cancer, 107, 8–14. https://doi.org/10.1016/j.ejca.2018.11.009
Chicago
Tobias L. Lenz, Fiamma Berner, David Bomze, Mirjam Fässler, Christoph Driessen, Martin Früh, Omar Ali, et al. 2019. “Human Leukocyte Antigen Variation Is Associated with Adverse Events of Checkpoint Inhibitors.” European Journal of Cancer 107 (January): 8–14. doi:10.1016/j.ejca.2018.11.009.